Financial Summary

Regeneron Pharmaceuticals Inc  (REGN)  $507.22    (%)

  • Symbol
    REGN
    Price
    507.22$
    Beta
    0.40579
    Volume Avrg.
    952800
    Market Cap
    54123418000
    Last Div
    0
    Range
    328.13-664.64
    Changes
    -16.39
    Changes Percentage
    Exchange
    Nasdaq Global Select
    Industry
    Biotechnology
    Ceo
    Dr. Leonard Schleifer
    Sector
    Healthcare

About company

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva; Mitsubishi Tanabe Pharma; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Vyriad, Inc., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and BioNTech. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.


Income Statement

YearRevenueCost of revenuesGross profitOperating expensessOperating incomesInterest expenseIncome tax expensesEarnings before taxsNet incomeEarnings per share basicsEarnings per share dilutedsDividend per sharesGross marginsEBIT marginsProfit marginsEBITDAEBITEarnings Before Tax MarginsNet Profit Margins
2020220747.00 151286.00 104956.00 38668.0066288.002873.00968.0067091.0057411.003.308587268217793.280.8033334143460.4754583301250.3002894716580.26007601462377344.0066288.000.3039271201870.260076014623
2019260174.00 161782.00 98392.00 34462.006393.003576.0010481.0065737.0055256.0011.9711.893.037054038220.378177681090.2457201718850.2123809450676477.006393.000.2526655238420.21238094506
2018265595.00 163756.00 101839.00 30941.0070898.00324.0013372.0072903.0059531.0012.0111.912.742340216980.38343718820.2669402661950.22414202074681801.0070898.000.2744893540920.224142020746
2017229234.00 141048.00 88186.00 26842.0061344.002323.0015738.0064089.0048351.009.279.212.431406868490.3846986049190.2676042820870.21092420845171501.0061344.000.2795789455320.210924208451
2016215639.00 131376.00 84263.00 24239.0060024.001456.0015685.0061372.0045687.008.358.312.208978050390.3907595564810.2783541010670.21186798306470529.0060024.000.2846052893960.211867983064
2015233715.00 140089.00 93626.00 22396.007123.00733.0019121.0072515.0053394.009.289.221.995660676580.4005990201740.3047729071730.22845773698782487.007123.000.3102710566290.228457736987
2014182795.00 112258.00 70537.00 18034.0052503.00384.0013973.0053483.003951.006.496.451.8171831440.3858803577780.2872233923250.21614376760960449.0052503.000.2925845892940.216143767609
201317091.00 106606.00 64304.00 15305.0048999.00136.0013118.0050155.0037037.0040.0339.7511.3388761160.3762448072080.2866947516240.21670469837955756.0048999.000.2934585454330.216704698379
2012156508.00 87846.00 68662.00 13421.0055241.000.001403.0055763.0041733.0044.6444.152.631815561350.4387123980880.352959593120.26665090602458518.0055241.000.3562948858840.266650906024
2011108249.00 64431.00 43818.00 10028.003379.000.008283.0034205.0025922.0028.0527.680.00.4047889587890.3121506896140.23946641539435604.003379.000.3159844432740.239466415394
201065225.00 39541.00 25684.00 7299.0018385.000.004527.001854.0014013.0015.4115.150.00.3937753928710.2818704484480.21484093522419412.0018385.000.2842468378690.214840935224
200942905.00 25683.00 17222.00 5482.001174.000.003831.0012066.008235.001.3171.2970.00.40140.28120.192128.0012066.000.28120.1919
Year202020192018201720162015201420132012201120102009
Revenue220747.00260174.00265595.00229234.00215639.00233715.00182795.0017091.00156508.00108249.0065225.0042905.00
Cost of revenues151286.00161782.00163756.00141048.00131376.00140089.00112258.00106606.0087846.0064431.0039541.0025683.00
Gross profit 104956.00 98392.00 101839.00 88186.00 84263.00 93626.00 70537.00 64304.00 68662.00 43818.00 25684.00 17222.00
Operating expensess38668.0034462.0030941.0026842.0024239.0022396.0018034.0015305.0013421.0010028.007299.005482.00
Operating incomes66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.001174.00
Interest expense2873.003576.00324.002323.001456.00733.00384.00136.000.000.000.000.00
Income tax expenses968.0010481.0013372.0015738.0015685.0019121.0013973.0013118.001403.008283.004527.003831.00
Earnings before taxs67091.0065737.0072903.0064089.0061372.0072515.0053483.0050155.0055763.0034205.001854.0012066.00
Net income57411.0055256.0059531.0048351.0045687.0053394.003951.0037037.0041733.0025922.0014013.008235.00
Earnings per share basics3.3085872682177911.9712.019.278.359.286.4940.0344.6428.0515.411.317
Earnings per share diluteds3.2811.8911.919.218.319.226.4539.7544.1527.6815.151.297
Dividend per shares0.83.042.742.432.2121.8211.342.63000
Gross margins0.480.380.380.380.390.40.390.380.440.40.390.4
EBIT margins0.30.250.270.270.280.30.290.290.350.310.280.28
Profit margins0.260.210.220.210.210.230.220.220.270.240.210.19
EBITDA77344.0076477.0081801.0071501.0070529.0082487.0060449.0055756.0058518.0035604.0019412.00128.00
EBIT66288.006393.0070898.0061344.0060024.007123.0052503.0048999.0055241.003379.0018385.0012066.00
Earnings Before Tax Margins0.30.250.270.280.280.310.290.290.360.320.280.28
Net Profit Margins0.260.210.220.210.210.230.220.220.270.240.210.19